{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-049048","form_type":"8-K","ticker":"XAIR","cik":"0001641631","company_name":"Beyond Air, Inc.","filed_at":"2024-12-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.074802+00:00","generated_at":"2026-05-29T06:37:14.721721+00:00","sec_items":["8.01","9.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Beyond Cancer (Beyond Air) gets Israeli MoH approval for Phase 1b LV UNO + anti-PD-1 trial for solid tumors","bullets":["Israeli Ministry of Health approved Phase 1b trial of LV UNO in combination with anti-PD-1 therapy for solid tumors.","Trial will enroll up to 20 patients with unresectable solid tumors that progressed or were stable on PD-1 inhibitors.","Primary endpoint: objective response rate (ORR) and duration of response per RECIST v1.1; secondary immune-related response.","Four Israeli sites; patient screening Q1 2025; topline data expected second half of 2025.","Preclinical data showed single UNO dose increased PD-L1 expression and improved survival vs anti-PD-1 alone."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-049048","json":"https://secwatch.observer/filing/0001493152-24-049048.json","markdown":"https://secwatch.observer/filing/0001493152-24-049048.md","text":"https://secwatch.observer/filing/0001493152-24-049048.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1641631/000149315224049048/0001493152-24-049048-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1641631/000149315224049048/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-29T06:37:14.721721+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}